

Annual General Meeting

Disclaimer

DISCLAIMER

This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

FUTURE MATTERS

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US DISCLOSURE

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1933 (“Securities Act”). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.



Board and Management Structure



Dr John Prendergast
Executive Chairman



James Graham
Chief Executive Officer



Michele Dilizia
Chief Scientific Officer



Justin Ward
Executive Director & Principal
Quality Chemist



Dr Alan Dunton
Non-Executive Director



Alistair McKeough
Non-Executive Director



Arthur Kollaras
Principle Engineer &
Head of Manufacturing



Justin Reynolds
Outsourced CFO



Maggie Niewidok
Company Secretary

Goals Stated at AGM 2021

AGM Presentation, Slide 8, 22 Nov 2021

Clinical Objectives

- ▶ **Phase I (R327) Intravascular Clinical Trial** – Patient dosing on track for December ✓
- ▶ **Phase I/II (R327) spray-on antibiotic burn wound studies** – Broad Spectrum antibiotic resistant infections among patients dosed ✓

Pre-Clinical Objectives

- ▶ **R327 Australia COVID studies** – Advanced to Stage 2 of the program ✓
- ▶ **R327 & R529 COVID (US)** – ‘gold standard’ animal study model underway ✓
- ▶ **Murdoch Children’s Research Institute - *H. pylori*, Sinusitis *in-vivo* studies, dose optimisation** ✓
- ▶ **Mechanism of Action (MoA) studies** – Expanded mechanistic insights, journal submission/s – world first ✓

Corporate Objectives

- ▶ **Continue big-pharma discussions** – position of power with unique MoA & strong cash position ✓
- ▶ **Expand international awareness** – particular focus on USA and EU ✓
- ▶ **Intellectual Property will continue to strengthen**
– Strong patent standing & Regulatory Incentive Focused ✓
- ▶ **New Clinical trials to begin** – Expect existing activities to bring online new clinical trials e.g. *diabetic foot ulcers* ✓

Recce has delivered!

12 Months of Announcements


Since our last AGM:

- ▶ Update on Phase I/II Clinical Trial for Burn Wound Infection (07/12/21)
- ▶ First Patients to be Dosed in Phase I I.V. Clinical Trial of R327 (15/12/21)
- ▶ Positive Safety Data from Cohort 1 Phase I I.V. Clinical Trial (07/01/22)
- ▶ Positive Safety Data from Second Cohort of Phase I I.V. Clinical Trial (18/01/22)
- ▶ Positive Initial Safety Data from Third Cohort of Phase I I.V. Clinical Trial (08/02/22)
- ▶ Final Subjects Dosed in Cohort 3 Phase I I.V. Clinical Trial (21/02/22)
- ▶ Safety Committee Clears Phase I I.V. R327 Dose Increase (07/03/22)
- ▶ \$3.08m R&D Rebate Received (28/03/22)
- ▶ Positive safety data from 4th Cohort Phase I I.V. Clinical Trial (30/03/22)
- ▶ Anti-Viral Patent Granted in Hong Kong (11/04/22)
- ▶ Phase I Clinical Trial R327 Advances to High Dose Cohort 2,000mg (12/04/22)
- ▶ Phase I I.V. Clinical Trial R327 Advances to 4000mg (20/05/22)
- ▶ Phase I I.V. Positive Safety Data - 4000mg Complete (21/06/22)
- ▶ Appointment of Dr Philip Sutton as V.P. of Translational Sciences (11/07/22)
- ▶ Phase I Clinical Trial of R327 I.V. 6000mg Complete (22/08/22)
- ▶ Appointment of Alistair McKeough to Board of Directors (01/09/22)
- ▶ Appointment of Dr John Prendergast as Executive Chairman (05/09/22)
- ▶ Michele Dilizia, CSO, delivers Opening R&D Address at World AMR Congress (07/09/22)
- ▶ Expansion and Acceleration of Clinical Programs (27/09/22)
- ▶ R327 COVID Study Update (18/10/22)
- ▶ Anti-Infective Portfolio Update and Webinar (19/10/22)




A Versatile Technology Platform

- Biotech company developing **Anti-infectives** targeting both bacterial and viral indications
- **Strong IP** and **own manufacturing** capability
- Qualified Infectious Disease Product designation
 - 10 years market exclusivity plus fast track approval*
- **Versatile delivery platform** – oral, intravenous and topical formulations
- Designed to safely provide treatment **without developing resistance** over time
- Multiple infectious disease opportunities with RECCE® 327



Strong Pipeline

Over Various Indications and Upcoming Inflection Points



*Anti-bacterial program

**Anti-viral program


Phase I Intravenous Human Clinical Trial

- Study to assess IV infusion of RECCE® 327 in 80 healthy male subjects as a single ascending dose.
- Randomized, double-blind, placebo-controlled, safety, tolerability and pharmacokinetics study.
- Single dose of a 1-hour via IV infusion at a uniform rate in hospital setting.
- Primary endpoint: vital signs, 12-lead ECG parameters, clinical chemistry, hematology, and urinalysis.





*Dose increase fold based off 50mg

Reason for Optimism in Treating UTI/Sepsis



Dr Alan Dunton's Clinical Update



Concentration of R327 in Urine Compared to Plasma

In over 60 healthy subjects

Ratio Urine/Plasma -
15x
13x
15x
17x
14x
20x
13x

- **R327 primary route of elimination** appears to be through the kidney to the ureters and bladder.
- **High concentrations of R327** noted in the urine of Phase I healthy subjects.
- **Insight consistent** with pre-clinical *in-vivo* kidney and UTI bacterial infection studies.

- **Opportunities for therapeutic** in array of UTIs (uncomplicated UTI - single dose, complicated UTI, recurrent UTI, treatment resistant etc).
- Suggests **broader anti-infective treatment model** in pre-sepsis.



Pre-Clinical Study Outlook

▶ Murdoch Children's Research Institute

- ▶ **Bacterial Sinusitis** - Sufficient and compelling data -potential to start a Phase I/II clinical trial
- ▶ ***M. abscessus*** - Proof of concept achieved – Compelling data for a potential human study
- ▶ ***H. pylori*** - Further formulation work and dosing optimisation required to improve delivery to site of infection

▶ Mechanism of Action studies

- ▶ Results confirm that R327 is broad spectrum, bactericidal, effective against growing and non-growing cells

▶ R327 COVID Study (Netherlands)

- ▶ R327 was shown to significantly reduce SARS-CoV-2 levels in the throat in a dose-dependent manner



Dr Philip Sutton's Pre-Clinical Update

Asset and Route of Administration	Indications	Discovery	Pre-Clinical	Phase I	Phase II
RCE Compounds*	Bacterial Sinusitis pre-clinical program				
	<i>Helicobacter pylori</i> pre-clinical program				
	<i>Mycobacterium abscessus</i> pre-clinical program				



Topical RECCE® 327 – Phase I/II

Patient examples from ongoing Burn Wound trial


- Patients suffered major burn injury.
- Multiple bacterial species in and surrounding wound.
- Growth swabs with organisms including pathogens from the ESKAPE group of bacteria.
- **Post R327 treatment: healthy skin growth return, reduced swelling and infection, indications of tissue penetration to underlying infection.**

Study data now under-review for next-step considerations.

- Building upon the success of these results, the Company has built out its topical treatment programs to include a new Phase II clinical study for Diabetic Foot Ulcer infections.



*Pre-treatment, significant
bacterial infection*



Post R327 treatment



Phase II Diabetic Foot Ulcer (DFU) Clinical Trial

Clinical Trial Overview

- The Phase II DFU Clinical Trial is expected to be **held at a leading Australian teaching hospital.**
- The clinical trial will assess R327 as a spray-on (topical) broad-spectrum antibiotic therapy for mild skin and soft tissue diabetic foot ulcers (DFU).

Market Opportunity

- The total medical cost for treating diabetic foot diseases in the United States is US \$9-13 billion every year.¹
- DFU is a chronic and devastating condition affecting an estimated 43,147,000 (13%) of the United States population.¹



Recce Executives and NSW Health Clinical Trial Team

Upcoming Clinical Milestones

- ***In-vivo pre-clinical***

- Pre-Sepsis UTI Models in Rats ✓

- **Phase I clinical trials**

- R327 I.V. Single Dose, Safety/Tolerability/PK study in healthy subjects ✓

- **Phase II UTI clinical trial (Pre-Sepsis)**

- Single (as now completed Phase I) efficacy study – Q1 2023
- Multiple-dose treatment of UTIs - complicated/resistant/chronic/etc. H1 2023

- **Phase Ib/Ila Sepsis clinical trial**

- R327 I.V. Multiple Dose, Safety/Tolerability/PK study in healthy subjects (First patient dosing Q4 2022)
- Multiple-Dose efficacy study in **urosepsis*** (sepsis derived from UTI infections) – efficacy signal

- **Phase II Diabetic Foot Ulcer (DFU) clinical trial**

- R327 as a spray-on (topical) broad-spectrum antibiotic for mild skin and soft tissue DFU (First patient dosing expected Q4 2022)



Michele Dilizia Scientific Strategy Update



2022 Corporate Goals



New Clinical Data Sets

Phase I Intravenous Study data sets to be released



Global Strategy - Partnerships

Continued engagement in partnership opportunities with both domestic and international organisations



Strengthen Intellectual Property

Including internationally recognised drug designations



Peer-Reviewed Publications

Recognition of R327's Unique Mechanism of Action unique with clinical context




Recce Pharmaceuticals Ltd – Capital Structure

Snapshot

Tickers	ASX:RCE, FSE:R9Q
Market Cap (approx.) Priced at \$0.66	AUD \$114.86 million
Cash and deposits* 28 October 2022	AUD \$5.73 million
Outstanding shares	178.08 million
Average daily volume 3 months	81.81k
Debt	Nil

**Pre >\$3.5m R&D rebate + other non-dilutionary cash in-flows expected this quarter - actual cash runway circa AUD \$10 million*



Thank you

James Graham

Chief Executive Officer

Recce Pharmaceuticals

ASX:RCE, FSE:R9Q

☎ +61 2 9256 2571

✉ james.graham@recce.com.au



recce.com.au